DNA

Co-Diagnostics, Inc. Honored at Utah Business 2025 Innovation Awards Summit

SALT LAKE CITY, Sept. 9, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with…

5 months ago

Pathwork Raises $3.5M to Replace Decades-Old Insurance Workflows with AI

The company's AI-native platform automates how life & health policies are sold, placed, and retained SAN FRANCISCO, Sept. 9, 2025…

5 months ago

Pathwork Raises $3.5M to Replace Decades-Old Insurance Workflows with AI

The company's AI-native platform automates how life & health policies are sold, placed, and retained SAN FRANCISCO, Sept. 9, 2025…

5 months ago

Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer

16.0 months median progression free survival (mPFS) with firmonertinib 240 mg by blinded independent central review (BICR) in first-line patientsConfirmed…

5 months ago

Sight Sciences Announces the OMNI® Surgical System to be Included in UnitedHealthcare’s® Expanded Coverage of Glaucoma Surgical Treatments

UnitedHealthcare’s Coverage Policy includes procedures enabled with OMNI Surgical System technology, the leader in implant-free MIGS, are proven and medically…

5 months ago

RYBREVANT®▼ (amivantamab) en association avec LAZCLUZE®▼ (lazertinib) réduit la résistance acquise à l’osimertinib dans le traitement de première intention du cancer du poumon non à petites cellules avancé avec mutations de l’EGFR

De nouvelles données démontrent que l’association avec l’amivantamab réduit significativement les mutations courantes de résistance à l’EGFR et au MET…

5 months ago

Exousia Pro Announces Strategic Acquisition to Launch a New Telehealth Division

Exousia Health is expected to have an initial patient base of 1,000 active clients, projected to generate approximately $50,000 in…

5 months ago

New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEM

Long-Term Data Adds to the Growing Body of Evidence Supporting the Compelling Clinical Profile of Pombiliti® + Opfolda®PRINCETON, N.J., Sept.…

5 months ago